Table 1. Characteristics of the patients with heart failure (n=39).
| Age, years | 81.0 [73, 87.5] |
| Female, n (%) | 14 (35.9) |
| Body mass index, kg/m2 | 21.9 [19.3, 24.2] |
| Charlson Comorbidity Index, scores | 2.5 [2, 4] |
| Eemployment, n (%) | 7 (17.9) |
| Live-together, n (%) | 32 (82.1) |
| Hospitalization for HF, n (%) | 1 [0, 2] |
| Hospitalization for HF, days | 18 (46.2) |
| BI before hospital, scores | 100 [95, 100] |
| NYHA, n (%) | |
| I | 2 (5.1) |
| II | 20 (51.3) |
| III | 17 (43.6) |
| LVEF classification, n (%) | |
| HFpEF | 16 (41.0) |
| HFmrEF | 9 (23.1) |
| HFrEF | 14 (35.9) |
| LVEF, % | 45.0 ± 18.6 |
| Medications, n (%) | |
| RAS inhibitors | 26 (66.6) |
| β-blockers | 22 (56.4) |
| Diuretics | 34 (87.2) |
| Digitalis | 6 (15.4) |
| Statins | 10 (25.6) |
| Anticoagulant | 9 (23.1) |
| Antiplatelet | 10 (25.6) |
| Underlying disease, n (%) | |
| Hypertension | 18 (46.2) |
| IHD | 11 (28.2) |
| Valvular | 11 (28.2) |
| Arrhythmia | 4 (10.3) |
| Others | 6 (15.4) |
| Laboratory findings | |
| BNP, pg/mL | 650 [243, 1,099] |
| Albumin, g/dL | 3.52 (0.44) |
| Hemoglobin, g/dL | 11.57 (2.38) |
| Creatinine, mg/dL | 1.2 [0.8, 1.7] |
| eGFR, mL/min/1.73 m2 | 42.7 [28.3, 60.4] |
| Hand-Grip strength, kg | 19.5 ± 10.1 |
| SAS, Mets | 3.5 [2.5, 6.5] |
| Length of stay, days | 17.0 [11.0, 21.5] |
The data are mean ± SD or median [25th, 75th percentile]. BI: Barthel Index; BNP: brain natriuretic peptide; eGFR: estimated glomerular filtration rate; HF: heart failure; HFmrEF: heart failure with mid-range ejection fraction; HFpEF: heart failure with preserved ejection fraction; HFrEF: heart failure with reduced ejection fraction; IHD: ischemic heart disease; LVEF: left ventricular ejection fraction; NYHA: New York Heart Association functional classification; RAS: renin-angiotensin system; SAS: Specific Activity Scale.